124 related articles for article (PubMed ID: 16091048)
21. Beta-lactam congeners of orlistat as inhibitors of fatty acid synthase.
Zhang W; Richardson RD; Chamni S; Smith JW; Romo D
Bioorg Med Chem Lett; 2008 Apr; 18(7):2491-4. PubMed ID: 18343106
[TBL] [Abstract][Full Text] [Related]
22. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
23. Identification of diacylglycerol and triacylglycerol containing 11,12,13-trihydroxy-9,14-octadecadienoic acid in castor oil.
Lin JT; Chen GQ
N Biotechnol; 2011 Feb; 28(2):203-8. PubMed ID: 20951848
[TBL] [Abstract][Full Text] [Related]
24. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG.
Parrish NM; Ko CG; Hughes MA; Townsend CA; Dick JD
J Antimicrob Chemother; 2004 Oct; 54(4):722-9. PubMed ID: 15355939
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of non-tuberculous pulmonary mycobacteriosis].
Sakatani M; Nakajima Y
Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
[TBL] [Abstract][Full Text] [Related]
26. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of isonicotinoylhydrazones from anacardic acid and their in vitro activity against Mycobacterium smegmatis.
Swamy BN; Suma TK; Rao GV; Reddy GC
Eur J Med Chem; 2007 Mar; 42(3):420-4. PubMed ID: 17112641
[TBL] [Abstract][Full Text] [Related]
28. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
29. [New information on the structure of mycobacteria].
Lagrange PH
Rev Pneumol Clin; 1994; 50(5):199-206. PubMed ID: 7899753
[TBL] [Abstract][Full Text] [Related]
30. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
[TBL] [Abstract][Full Text] [Related]
31. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37Rv.
Lin X; Xu S; Yang Y; Wu J; Wang H; Shen H; Wang H
Protein Expr Purif; 2009 Mar; 64(1):8-15. PubMed ID: 18952181
[TBL] [Abstract][Full Text] [Related]
32. Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii: novel structural features and apoptosis-inducing properties.
Guérardel Y; Maes E; Briken V; Chirat F; Leroy Y; Locht C; Strecker G; Kremer L
J Biol Chem; 2003 Sep; 278(38):36637-51. PubMed ID: 12829695
[TBL] [Abstract][Full Text] [Related]
33. Fullerene isoniazid conjugate--a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity.
Kumar A; Patel G; Menon SK
Chem Biol Drug Des; 2009 May; 73(5):553-7. PubMed ID: 19366360
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of mycolic acid subclass and molecular species composition of Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105).
Uenishi Y; Fujita Y; Kusunose N; Yano I; Sunagawa M
J Microbiol Methods; 2008 Feb; 72(2):149-56. PubMed ID: 18178279
[TBL] [Abstract][Full Text] [Related]
35. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K; Mezo G; Szabó N; Hudecz F; Bosze S
J Pept Sci; 2009 May; 15(5):385-91. PubMed ID: 19319854
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
[TBL] [Abstract][Full Text] [Related]
37. The oriented development of antituberculotics: salicylanilides.
Waisser K; Matyk J; Divisová H; Husáková P; Kunes J; Klimesová V; Kaustová J; Möllmann U; Dahse HM; Miko M
Arch Pharm (Weinheim); 2006 Nov; 339(11):616-20. PubMed ID: 17048291
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach.
Rao GS; Kumar M
Chem Biol Drug Des; 2008 Jun; 71(6):540-5. PubMed ID: 18482337
[TBL] [Abstract][Full Text] [Related]
39. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
[TBL] [Abstract][Full Text] [Related]
40. Crucial components of Mycobacterium type II fatty acid biosynthesis (Fas-II) and their inhibitors.
Duan X; Xiang X; Xie J
FEMS Microbiol Lett; 2014 Nov; 360(2):87-99. PubMed ID: 25227413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
